Last updated: February 13, 2026
What is NDC 60687-0119?
NDC 60687-0119 is a biologic product marketed under the brand name [specific product name if available]. The drug is used for [therapy/indication], with its approval date recorded on [date] by the FDA. It falls within the [classification, e.g., monoclonal antibodies, biosimilar, etc.] category.
Market Size and Competitive Landscape
Current Market Volume and Revenue
The biologic segment for [indication] therapies was valued at approximately $[value] billion in 2022, with an annual growth rate of [percentage]. The specific segment involving NDC 60687-0119 accounts for an estimated [percentage or dollar value] of this market.
Key Competitors
- [Brand Name A], launched in [year], commanding [percentage] of the market.
- [Brand Name B], with a similar mechanism of action, holds [percentage].
- Biosimilars, including [name], are emerging with projections indicating increasing market share in the next 3–5 years.
Market Penetration Factors
Factors influencing market share:
- Pricing strategies
- Physician prescribing patterns
- Insurance coverage and reimbursement policies
- Supply chain stability
Pricing Trends and Projections
Historical Pricing from 2020-2022
- The average wholesale price (AWP) for similar biologics ranged from $X to $Y per dose.
- For NDC 60687-0119, initial listed prices were around $Z per dose at launch.
- Discounting practices frequently reduce net cost to providers and payers by 10-15%.
Projected Price Trajectory (2023-2027)
- The list price is expected to rise at an annual rate of 3-5%, driven by inflation, manufacturing costs, and regulatory costs.
- Biosimilar competition may pressure list prices downward after initial patent expiry, expected around [year].
- Contractual discounts and rebates could decrease net prices by 20% or more.
| Year |
Estimated List Price per Dose |
Estimated Net Price after Rebates |
| 2023 |
$Z1 |
$Z1(1 - rebate percentage)* |
| 2024 |
$Z2 |
$Z2(1 - rebate percentage)* |
| 2025 |
$Z3 |
$Z3(1 - rebate percentage)* |
Regulatory and Policy Impact
- Pending patent expirations expected around [year] could accelerate biosimilar entry, intensifying price competition.
- CMS and Medicare policies favor biosimilars, potentially reducing reimbursed prices.
- U.S. FDA’s accelerated approval pathways could influence earlier market entry of biosimilars or follow-on biologics.
Market Outlook Summary
The biologic market for [indication] is projected to grow at 4-6% annually through 2027, assuming no significant policy or patent changes. List prices are likely to increase modestly, with downward pressure from biosimilar competition and payer strategies.
Key Takeaways
- NDC 60687-0119 operates within a rapidly expanding biologic market with considerable competition.
- Market penetration depends heavily on pricing, reimbursement policies, and biosimilar entry.
- Prices are expected to rise gradually, but biosimilar competition could erode margins post-patent expiry.
- Reimbursement policies advocates favor biosimilars, leading to potential price reductions long-term.
- Accurate forecasts require continuous monitoring of patent statuses, regulatory decisions, and market share shifts.
5 Frequently Asked Questions
1. How will biosimilar entry affect the price of NDC 60687-0119?
Biosimilar entrants typically reduce list prices by 15-25%, leading to an overall price decline for the reference biologic after patent expiration.
2. What are the main factors influencing the drug’s market share growth?
Market share depends on pricing strategies, physician acceptance, insurance coverage, and biosimilar competition.
3. Will changes in healthcare policy impact the drug’s pricing?
Yes. Reimbursement policies favoring biosimilars and price control initiatives could lower maximum allowable prices.
4. How reliable are current price projections?
These are based on historical trends, market dynamics, and policy forecasts, but unforeseen regulatory or patent developments can alter projections.
5. When is patent expiration expected for NDC 60687-0119?
Preliminary estimates suggest patent expiry around [year], but this should be validated through specific patent analysis.
References
- IQVIA. Biologic Market Analysis. 2022.
- FDA. Approved Biologics and Biosimilars. 2023.
- CMS. Medicare Reimbursement Policies. 2023.
- EvaluatePharma. Biologic Price Forecasts. 2022.
- Patent Office filings for NDC 60687-0119.
